MX2015003765A - Arterivirus. - Google Patents

Arterivirus.

Info

Publication number
MX2015003765A
MX2015003765A MX2015003765A MX2015003765A MX2015003765A MX 2015003765 A MX2015003765 A MX 2015003765A MX 2015003765 A MX2015003765 A MX 2015003765A MX 2015003765 A MX2015003765 A MX 2015003765A MX 2015003765 A MX2015003765 A MX 2015003765A
Authority
MX
Mexico
Prior art keywords
arteriviruses
plp2
arterivirus
arteriviral
competent
Prior art date
Application number
MX2015003765A
Other languages
English (en)
Inventor
Marjolein Kikkert
Brian Leonard Mark
Van Puck Bertyne Kasteren
Terrence William James
Eric John Snijder
Original Assignee
Univ Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba filed Critical Univ Manitoba
Publication of MX2015003765A publication Critical patent/MX2015003765A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10061—Methods of inactivation or attenuation
    • C12N2770/10062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a Arterivirus de replicación competente con una actividad disminuida de DUB/deISGilación debido a una mutación en el dominio de PLP2 de la proteína no estructural nsp2, para su uso como un medicamento, su uso como una vacuna y en profilaxis, a las vacunas que comprenden tales Arterivirus y a complejos Arterivirales PLP2-ubiquitina.
MX2015003765A 2012-09-26 2013-09-25 Arterivirus. MX2015003765A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12186162 2012-09-26
PCT/EP2013/069915 WO2014048955A1 (en) 2012-09-26 2013-09-25 Arterivirus

Publications (1)

Publication Number Publication Date
MX2015003765A true MX2015003765A (es) 2015-11-16

Family

ID=46924351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003765A MX2015003765A (es) 2012-09-26 2013-09-25 Arterivirus.

Country Status (10)

Country Link
US (2) US9457073B2 (es)
EP (1) EP2900257A1 (es)
JP (1) JP2015532269A (es)
KR (1) KR20150060744A (es)
CN (1) CN104812409A (es)
BR (1) BR112015006605A2 (es)
CA (1) CA2883591A1 (es)
MX (1) MX2015003765A (es)
RU (1) RU2015115486A (es)
WO (1) WO2014048955A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457073B2 (en) * 2012-09-26 2016-10-04 University Of Manitoba Live attenuated replication-competent arteriviruses having decreased dub/deisgylating activity
CN104497148B (zh) * 2014-12-17 2018-05-18 青岛明勤生物科技有限公司 一种重组泛素化蓝耳病疫苗的制备
CN108697782A (zh) 2016-03-23 2018-10-23 英特维特国际股份有限公司 针对pcv2病毒和猪肺炎支原体感染的组合疫苗
JP2019509302A (ja) 2016-03-23 2019-04-04 インターベット インターナショナル ベー． フェー． アルブミンを含むｐｃｖ２及びｐｒｒｓウイルス感染症に対する混合ワクチン
BR112018069219A2 (pt) 2016-03-23 2019-01-22 Intervet Int Bv uma vacina para aplicação intradérmica contra infecção pelo vírus pcv2 e prrs
CN105779651A (zh) * 2016-04-08 2016-07-20 浙江省淡水水产研究所 一种中华鳖动脉炎病毒快速检测试剂盒及其检测方法
BR112019010394A2 (pt) 2016-11-29 2019-09-03 Intervet Int Bv vacina suína
EP3609533A1 (en) 2017-04-13 2020-02-19 Intervet International B.V. Vaccines containing swine pathogens for associated non-mixed use
US20230338500A1 (en) 2020-04-20 2023-10-26 Intervet Inc. A combination of vaccines to prophylactically treat a pig
CN114778852B (zh) * 2022-04-26 2023-09-01 中国农业大学 一种检测prrsv plp2抗体的间接elisa方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101189027A (zh) * 2005-01-13 2008-05-28 贝林格尔·英格海姆维特梅迪卡有限公司 改良的prrs疫苗
WO2009008924A2 (en) 2007-04-05 2009-01-15 Mount Sinai School Of Medicine Of New York University Methods of preventing and treating viral infections by inhibiting the deisgylation activity of otu domain-containing viral proteins
KR20100058451A (ko) * 2007-06-25 2010-06-03 사우스다코타주립대학 재조합 북아메리카 타입 1 돼지 생식기 및 호흡기 증후군 바이러스 및 이의 사용 방법
UA108902C2 (uk) 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
MY186535A (en) 2011-02-17 2021-07-26 Boehringer Ingelheim Vetmedica Gmbh Novel european prrsv strain
JP6096176B2 (ja) * 2011-05-27 2017-03-15 シノヴェット （ベイジン） バイオテクノロジー カンパニー，リミテッド ブタウイルス感染の予防のための混合ワクチン
US9457073B2 (en) * 2012-09-26 2016-10-04 University Of Manitoba Live attenuated replication-competent arteriviruses having decreased dub/deisgylating activity

Also Published As

Publication number Publication date
US20140154265A1 (en) 2014-06-05
CA2883591A1 (en) 2014-04-03
RU2015115486A (ru) 2016-11-20
WO2014048955A1 (en) 2014-04-03
BR112015006605A2 (pt) 2017-10-10
US20150313988A1 (en) 2015-11-05
CN104812409A (zh) 2015-07-29
KR20150060744A (ko) 2015-06-03
JP2015532269A (ja) 2015-11-09
EP2900257A1 (en) 2015-08-05
US9457073B2 (en) 2016-10-04

Similar Documents

Publication Publication Date Title
MX2015003765A (es) Arterivirus.
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX2018012394A (es) Variantes de polipeptido ph20, formulaciones y usos de las mismas.
IN2015DN03322A (es)
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
IN2014DN09434A (es)
MX364229B (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2016008226A (es) Metodos para el cuidado oral prebiotico usando un sacarido.
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX2013004061A (es) Analogos de ciclosporina.
ZA201701000B (en) Attenuated bovine coronavirus and related vaccines
EA201590491A1 (ru) Иммуногенная композиция
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
GEP201706739B (en) Compositions comprising vortioxetine and donepezil
MX2013004062A (es) Analogos de ciclosporina.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX349485B (es) Composiciones de higiene bucal.
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
MD20140122A2 (ro) Procedee de producere a clorhidratului de anamorelin cu un conţinut controlat de clorură
MX2016001691A (es) Moleculas de union al receptor bag3 para uso como un medicamento.